Gainers
- NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) rose 54.6% to $26.07 in pre-market trading after the company entered into an exclusive license agreement with Dong-A.
- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) shares rose 28.6% to $0.2765 in pre-market trading. Sonnet BioTherapeutics, last month, posted a Q3 loss of $0.13 per share.
- Aditxt, Inc. (NASDAQ:ADTX) rose 24.9% to $14.28 in pre-market trading. Aditxt announced a 1-for-50 reverse stock split effective on September 14, 2022.
- Fast Radius, Inc. (NASDAQ:FSRD) rose 19.4% to $0.6260 in pre-market trading. The company, last month, posted upbeat quarterly results.
- Addentax Group Corp. (NASDAQ:ATXG) shares rose 16.3% to $5.56 in pre-market trading after jumping 17% on Wednesday.
- Austin Gold Corp. (NYSE:AUST) rose 11.7% to $1.53 in pre-market trading.
- Kuke Music Holding Limited (NYSE:KUKE) rose 11.7% to $0.7880 in pre-market trading after tumbing over 10% on Wednesday.
- Enochian Biosciences, Inc. (NASDAQ:ENOB) rose 11.1% to $2.00 in pre-market trading after declining around 6% on Wednesday.
- Ra Medical Systems, Inc. (NASDAQ:RMED) rose 10.2% to $0.1764 in pre-market trading. Ra Medical Systems recently announced a reverse merger agreement with Catheter Precision.
- Ensysce Biosciences, Inc. (NASDAQ:ENSC) rose 9.7% to $0.3950 in pre-market trading after declining around 13% on Wednesday.
- AMTD Digital Inc. (NYSE:HKD) rose 8.8% to $206.06 in pre-market trading after jumping 312% on Wednesday.
- Velo3D, Inc. (NYSE:VLD) rose 8.8% to $5.18 in pre-market trading after the company announced that Kevton Technologies had purchased seven of the company's Sapphire printers.
- Jaguar Health, Inc. (NASDAQ:JAGX) rose 8.1% to $0.2490 in pre-market trading. Jaguar Health recently submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration for its subsidiary Napo's NP-300 drug product candidate for the symptomatic relief of diarrhea from cholera.
- Altimmune, Inc. (NASDAQ:ALT) rose 4.6% to $15.56 in pre-market trading. Altimmune shares dropped 27% on Wednesday after the company announced topline results from its 12-week Phase 1b study of pemvidutide1 in subjects with non-alcoholic fatty liver disease.
